FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2244473630> ?p ?o ?g. }

• W2244473630 endingPage "149" @default.
• W2244473630 startingPage "149" @default.
• W2244473630 abstract "149 Background: The Temporary Authorizations for Use (ATU) procedure is an exceptional measure making available medicinal products that have not yet been granted a Marketing Authorisation. Abiraterone acetate (AA) was available for ATU since December 2010 in France. We then decided to evaluate the tolerance and efficacy of this treatment and identify predictive factors of response. Methods: 82 centers were contacted and clinical data were reported in two months (15 th July-19 th September 2011). Patients were defined as non-responders in case of interruption of AA due to disease progression or death. PSA values were recorded at each medical visit. Reported toxicities were also recorded. Statistical analyses were descriptive and predictive factors were determined. Results: A total of 18 centers accepted to participate in this study including 381 patients. Median age at diagnosis was 63 years. The Gleason score (n=320) were 4-6, 7, and 8-10 in 13.4%, 36.9% and 49.7%, respectively. Before AA, the type of metastasis was bone only, organs only, and bone+organs in 45.4%, 7.9% and 46.7%, respectively. Median PSA before CT and before AA was 58.1 and 137.5 ng/ml, respectively. Median duration of hormonotherapy (HT) before any CT was 34 months. Median duration of CT before AA was 6.1 months with a median number of CT lines of one. Median duration of AA was 117 days. In the non-responders group (n=114), median duration of AA was significantly shorter than in the responders group (n=267), 87 days vs 147 days, respectively (p<0.0001). One third of the patients in the responders group presented a PSA increase over time but continued AA as they clinically improved. Only 13 patients stopped AA for grade 3-4 toxicities. GIeason 8-10 and the number of CT lines (>1) before AA were identified as independent predictive factors of non response. Conclusions: This report is the largest ambispective observational study of AA in an ATU process. PSA values during AA treatment were used as a good indicator of progression. GIeason 8-10 and the number of CT lines (>1) before AA were identified as independent predictive factors and therefore could be used for further strategies in this setting." @default.
• W2244473630 created "2016-06-24" @default.
• W2244473630 creator A5005004507 @default.
• W2244473630 creator A5009585365 @default.
• W2244473630 creator A5012051564 @default.
• W2244473630 creator A5017343374 @default.
• W2244473630 creator A5021549650 @default.
• W2244473630 creator A5026180389 @default.
• W2244473630 creator A5026462289 @default.
• W2244473630 creator A5031202796 @default.
• W2244473630 creator A5032686530 @default.
• W2244473630 creator A5038456224 @default.
• W2244473630 creator A5042461515 @default.
• W2244473630 creator A5059690857 @default.
• W2244473630 creator A5059810021 @default.
• W2244473630 creator A5065732872 @default.
• W2244473630 creator A5067036952 @default.
• W2244473630 creator A5076657252 @default.
• W2244473630 creator A5090082356 @default.
• W2244473630 creator A5090993023 @default.
• W2244473630 creator A5091487792 @default.
• W2244473630 date "2012-02-10" @default.
• W2244473630 modified "2023-10-14" @default.
• W2244473630 title "An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response." @default.
• W2244473630 doi "https://doi.org/10.1200/jco.2012.30.5_suppl.149" @default.
• W2244473630 hasPublicationYear "2012" @default.
• W2244473630 type Work @default.
• W2244473630 sameAs 2244473630 @default.
• W2244473630 citedByCount "14" @default.
• W2244473630 countsByYear W22444736302012 @default.
• W2244473630 countsByYear W22444736302013 @default.
• W2244473630 countsByYear W22444736302014 @default.
• W2244473630 countsByYear W22444736302015 @default.
• W2244473630 countsByYear W22444736302018 @default.
• W2244473630 crossrefType "journal-article" @default.
• W2244473630 hasAuthorship W2244473630A5005004507 @default.
• W2244473630 hasAuthorship W2244473630A5009585365 @default.
• W2244473630 hasAuthorship W2244473630A5012051564 @default.
• W2244473630 hasAuthorship W2244473630A5017343374 @default.
• W2244473630 hasAuthorship W2244473630A5021549650 @default.
• W2244473630 hasAuthorship W2244473630A5026180389 @default.
• W2244473630 hasAuthorship W2244473630A5026462289 @default.
• W2244473630 hasAuthorship W2244473630A5031202796 @default.
• W2244473630 hasAuthorship W2244473630A5032686530 @default.
• W2244473630 hasAuthorship W2244473630A5038456224 @default.
• W2244473630 hasAuthorship W2244473630A5042461515 @default.
• W2244473630 hasAuthorship W2244473630A5059690857 @default.
• W2244473630 hasAuthorship W2244473630A5059810021 @default.
• W2244473630 hasAuthorship W2244473630A5065732872 @default.
• W2244473630 hasAuthorship W2244473630A5067036952 @default.
• W2244473630 hasAuthorship W2244473630A5076657252 @default.
• W2244473630 hasAuthorship W2244473630A5090082356 @default.
• W2244473630 hasAuthorship W2244473630A5090993023 @default.
• W2244473630 hasAuthorship W2244473630A5091487792 @default.
• W2244473630 hasConcept C108759981 @default.
• W2244473630 hasConcept C121608353 @default.
• W2244473630 hasConcept C126322002 @default.
• W2244473630 hasConcept C141071460 @default.
• W2244473630 hasConcept C23131810 @default.
• W2244473630 hasConcept C2775832370 @default.
• W2244473630 hasConcept C2777899217 @default.
• W2244473630 hasConcept C2780192828 @default.
• W2244473630 hasConcept C38652104 @default.
• W2244473630 hasConcept C41008148 @default.
• W2244473630 hasConcept C71924100 @default.
• W2244473630 hasConcept C72563966 @default.
• W2244473630 hasConceptScore W2244473630C108759981 @default.
• W2244473630 hasConceptScore W2244473630C121608353 @default.
• W2244473630 hasConceptScore W2244473630C126322002 @default.
• W2244473630 hasConceptScore W2244473630C141071460 @default.
• W2244473630 hasConceptScore W2244473630C23131810 @default.
• W2244473630 hasConceptScore W2244473630C2775832370 @default.
• W2244473630 hasConceptScore W2244473630C2777899217 @default.
• W2244473630 hasConceptScore W2244473630C2780192828 @default.
• W2244473630 hasConceptScore W2244473630C38652104 @default.
• W2244473630 hasConceptScore W2244473630C41008148 @default.
• W2244473630 hasConceptScore W2244473630C71924100 @default.
• W2244473630 hasConceptScore W2244473630C72563966 @default.
• W2244473630 hasIssue "5_suppl" @default.
• W2244473630 hasLocation W22444736301 @default.
• W2244473630 hasOpenAccess W2244473630 @default.
• W2244473630 hasPrimaryLocation W22444736301 @default.
• W2244473630 hasRelatedWork W1586374228 @default.
• W2244473630 hasRelatedWork W2003938723 @default.
• W2244473630 hasRelatedWork W2047967234 @default.
• W2244473630 hasRelatedWork W2118496982 @default.
• W2244473630 hasRelatedWork W2364998975 @default.
• W2244473630 hasRelatedWork W2369162477 @default.
• W2244473630 hasRelatedWork W2439875401 @default.
• W2244473630 hasRelatedWork W2603773853 @default.
• W2244473630 hasRelatedWork W4238867864 @default.
• W2244473630 hasRelatedWork W2525756941 @default.
• W2244473630 hasVolume "30" @default.
• W2244473630 isParatext "false" @default.
• W2244473630 isRetracted "false" @default.
• W2244473630 magId "2244473630" @default.
• W2244473630 workType "article" @default.